Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667733 | 0.80 | TP53 (0.33) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL23627436 | 0.79 | — | — | |
| SCHEMBL680376 | 0.79 | KMT2A (0.35) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL9290214 | 0.76 | KMT2A (0.32) | KMT2AKDM4E | |
| SCHEMBL24268083 | 0.75 | KMT2A (0.31) | KMT2A | |
| SCHEMBL112567 | 0.74 | TSHR (0.36) | — | |
| SCHEMBL21789491 | 0.73 | — | — | |
| SCHEMBL2980091 | 0.72 | KMT2A (0.34) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL6897806 | 0.72 | KMT2A (0.34) | KMT2AKDM4ESIGMAR1 | |
| SCHEMBL10596223 | 0.72 | KMT2A (0.34) | KMT2AKDM4ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220055997-A1 | ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS COMPRISING SAME | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-02-24 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | KMT2A 2833/4885KDM4E 2509/4885SIGMAR1 2548/4885 |
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | KMT2A 84/4885KDM4E 378/4885SIGMAR1 4523/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | KMT2A 2833/4885KDM4E 2509/4885SIGMAR1 2548/4885 |
| US-20220055997-A1 | ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS COMPRISING SAME | MPO, IMMT, CLPP | KMT2A 4651/4885KDM4E 4570/4885SIGMAR1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.